Menu
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.
1000 Winter St
Waltham, Massachusetts 02451-1436
Phone: 17818909989
www.neurometrix.com
In recent trading session, NeuroMetrix Inc. (NASDAQ:NURO) saw 9.21 million shares changing hands at last check today with its beta currently measuring 2.37. Company’s recent per share price level of $1.63 trading at $0.06 or 3.82% at last check today assigns it a market valuation of $11.93M. That most recent trading price of NURO’s stock … NeuroMetrix Inc. (NASDAQ:NURO) Rises 3.82%, But An Additional Surge May Follow. Read More »
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the symptoms of fibromyalgia.
NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q3 2022 Earnings Conference Call October 20, 2022, 8:00 am ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - CEO Conference Call…
NeuroMetrix press release (NURO): Q3 net loss of $1.6MRevenue of $2M (-4.8% Y/Y).
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
Companies Reporting Before The Bell • ABB (NYSE: ABB ) is estimated to report quarterly earnings at $0.38 per share on revenue of $7.35 billion. • Nokia (NYSE: NOK ) is expected to report quarterly earnings at $0.10 per share on revenue of $6.32 billion. • Telefonaktiebolaget L M (NASDAQ: ERIC ) is estimated to report quarterly earnings at $0.16 per share on revenue of $6.18 billion. • Quest Diagnostics (NYSE: DGX ) is projected to report quarterly earnings at $2.17 per share on revenue of $2.33 billion. • Banc of California (NYSE: BANC ) is projected to report quarterly earnings at $0.47 per share on revenue of $84.68 million. • Nucor (NYSE: NUE ) is likely to report quarterly earnings at $6.69 per share on revenue of $10.03 billion. • CLPS (NASDAQ: CLPS ) is estimated to report earnings for its Fiscal Year 2022. • Alaska Air Gr (NYSE: ALK ) is likely to report quarterly earnings at $2.40 per share on revenue of $2.82 billion. • NeuroMetrix (NASDAQ: NURO ) is expected to report earnings for its third quarter.
Relmada Therapeutics RLMD -79% as depression therapy REL-1017 fails phase 3 trial.T2 Biosystems TTOO -25% on revised annual guidance, executes reverse stock split.Argo…
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to discuss its financial results as well as business developments affecting the Company.
Dice Therapeutics DICE +70%. Albireo Pharma ALBO +15%. Orthofix Medical OFIX -20%. NeuroMetrix (NURO) -17%.
Green Giant (GGE) -12%.Argo Blockchain ARBK -12% after mines ~8.5% lower bitcoins in September.NeuroMetrix (NURO) -11%.Fujian Blue Hat Interactive Entertainment Technology (BHAT)…
In Monday’s session, NeuroMetrix Inc. (NASDAQ:NURO) marked $2.84 per share, up from $2.83 in the previous session. While NeuroMetrix Inc. has overperformed by 0.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NURO fell by -68.09%, with highs and lows ranging from $9.85 to $2.67, whereas […]
